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The Joint Commission Journal on Quality and Patient Safety
When Is Antipsychotic Polypharmacy Supported by Research
Evidence? Implications for QI
Performance Measures
Antipsychotic drugs have demonstrated efficacy andeffectiveness for the treatment of schizophrenia andother psychotic disorders.1 In addition, certain tradi-
tional antipsychotics are approved by the Food and Drug
Administration (FDA) for treatment of Tourette’s syndrome
and mania, whereas selected second-generation antipsychotics
(SGAs) have additionally received approval for bipolar disorder
(manic and maintenance phases) and as adjunctive treatment
for treatment-resistant depression.2–6
High rates of antipsychotic polypharmacy, defined as the
concurrent use of more than one standing antipsychotic drug
among patients treated with an antipsychotic, have been
observed in numerous studies.7–28 Rates vary widely, depending
on the population, setting, and how polypharmacy is measured.
On the basis of the threshold of two or more antipsychotics,
studies of acutely hospitalized patients report rates of
30%–40%,8,9,11,12 whereas studies of outpatient samples (across
the Department of Veterans Affairs, Medicaid, and state men-
tal health systems) report rates of 11%–35%.13,14,16 Less infor-
mation is available on concurrent use of more than two
antipsychotics; one study reported that 4.6% of inpatients were
on three or more antipsychotics.8 Most of these studies lack
information on the degree to which use of multiple antipsy-
chotics was clinically appropriate. Medical records typically
lack the necessary documentation to make this determination,
including the patient’s history of previous antipsychotic trials
and their outcomes or other rationales for polypharmacy.29–31
The extent of antipsychotic polypharmacy has been viewed
with mounting concern, resulting in many calls for reducing its
use.15,16,19,32–36 Clinically, antipsychotic polypharmacy has the
potential to cause increased side effects and drug interactions.
Increasing the number of medications prescribed can lead to a
decline in patient adherence.37,38 Financially, the high cost of
SGAs has strained state Medicaid and mental health budgets,
leading some states to impose formulary restrictions limiting or
delaying their use.32,34,39,40
Measurement-based quality improvement (QI) is a method
Article-at-a-Glance
Background: Concurrent use of multiple standing antipsy-
chotics (antipsychotic polypharmacy) is increasingly com-
mon among both inpatients and outpatients. Although this
has often been cited as a potential quality-of-care problem,
reviews of research evidence on antipsychotic polypharma-
cy have not distinguished between appropriate versus inap-
propriate use.
Methods: A MEDLINE search from 1966 to December
2007 was completed to identify studies comparing changes
in symptoms, functioning, and/or side effects between
patients treated with multiple antipsychotics and patients
treated with a single antipsychotic. The studies were
reviewed in two groups on the basis of whether prescribing
was concordant with guideline recommendations for mul-
tiple-antipsychotic use.
Results: A review of the literature, including three ran-
domized controlled trials, found no support for the use of
antipsychotic polypharmacy in patients without an estab-
lished history of treatment resistance to multiple trials of
monotherapy. In patients with a history of treatment resist-
ance to multiple monotherapy trials, limited data support
antipsychotic polypharmacy, but positive outcomes were
primarily found in studies of clozapine augmented with a
second-generation antipsychotic.
Discussion: Research evidence is consistent with the goal
of avoiding antipsychotic polypharmacy in patients who
lack guideline-recommended indications for its use. The
Joint Commission is implementing a core measure set for
Hospital-Based Inpatient Psychiatric Services. Two of the
measures address antipsychotic polypharmacy. The first
measure assesses the overall rate. The second measure deter-
mines whether clinically appropriate justification has been
documented supporting the use of more than one antipsy-
chotic medication. 
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used by hospitals and other provider organizations to assess and
improve their clinical practices. QI priorities are often estab-
lished by external organizations, such as payers or accreditors,
by implementing quality measures. Hospitals, for example, are
required to report their performance on standardized core mea-
sures. External groups then use the results in one or more ways
to encourage hospitals to improve, such as providing hospitals
with feedback comparing their performance with peer organi-
zations, disclosing results publicly in an effort to influence pur-
chaser or consumer decisions, or linking financial incentives to
improved performance.41
Two national measurement-based QI initiatives are aimed at
decreasing unnecessary antipsychotic polypharmacy. The
National Association of State Mental Health Program Directors
Research Institute has implemented a measure of antipsychotic
polypharmacy rates in a number of state psychiatric hospitals.35
Effective October 1, 2008, The Joint Commission is imple-
menting a core measure set for Hospital-Based Inpatient
Psychiatric Services; two of the measures address antipsychotic
polypharmacy. The first measure assesses the hospital’s overall
rate. The second measure determines whether clinically appro-
priate justification has been documented when more than one
antipsychotic is used.36  The Joint Commission initiative is dis-
cussed further in the “Discussion” section (pages 579–580).
One factor limiting QI initiatives to reduce antipsychotic
polypharmacy has been a lack of clarity about the research evi-
dence regarding its use. Practice guidelines addressing multiple
antipsychotic use recommend the addition of a second antipsy-
chotic only after multiple trials of adequate duration of a single
antipsychotic.42–44 However, previous review articles evaluating
antipsychotic polypharmacy45,46 have not distinguished between
research studies of patients meeting this criterion and studies of
patients who do not.
This article reviews studies comparing outcomes of patients
receiving multiple antipsychotics with outcomes of patients
receiving antipsychotic monotherapy, first, among patients
with documented treatment resistance to multiple trials of a
single antipsychotic, and then, among patients without an
established history of treatment resistance to monotherapy.
Methods
In January 2008, we conducted a MEDLINE search from 1966
to December 2007 to identify studies comparing changes in
symptoms, functioning, and/or side effects between patients
treated with multiple antipsychotics and patients treated with a
single antipsychotic. The following search terms were used:
antipsychotic, polypharmacy, augmentation, treatment resistance,
combination, side effects, adverse reactions, quality, measure,
improvement, monotherapy, outcomes, multiple antipsychotics.
The reference sections of these articles and previous reviews
were searched for articles not identified in the original search.
Articles were restricted to the English language. Data on the
study design, drugs prescribed, and changes in symptoms,
functioning, and side effects were abstracted and reported. 
In keeping with guideline recommendations for multiple
antipsychotic use,42–44 we report findings from studies of
patients with a documented history of treatment resistance
(including partial response) to multiple trials of a single
antipsychotic separately from studies of patients without such a
history established. We examined studies within strata reflect-
ing the rigor of their study design: randomized controlled trials
(RCTs), nonrandomized controlled studies, and noncontrolled
observational studies. Because of the robust number of studies
with one of these designs, we excluded case reports and series
without statistical analyses. Major limitations of each study are
noted in the evidence tables; these include small sample sizes in
some studies, limited matching characteristics, and short peri-
ods before follow-up assessment. Unless otherwise noted, all
comparisons reported were statistically significant.
Results
SAMPLES WITH ESTABLISHED TREATMENT RESISTANCE
TO ANTIPSYCHOTIC MONOTHERAPY
We identified six RCTs comparing antipsychotic polypharma-
cy to monotherapy in samples with established treatment resist-
ance to trials of a single antipsychotic (Table 1, pages
573–575).47–52 All studies were of patients with schizophrenia or
schizoaffective disorder. Two studies found that patients on
multiple antipsychotics, compared with patients on a single
antipsychotic, experienced greater improvement in the primary
clinical outcome (that is, symptoms or functioning).50,52 Three
trials found no difference in the primary clinical outcome
between patients on single and multiple antipsychotics.48,49,51
One trial reported better clinical outcomes for patients on a sin-
gle antipsychotic.47 Four of the six trials reported comparative-
ly greater side effects for patients on multiple antipsychotics,
whereas two found no differences in side effects.47–49,52 One trial
reported that risperidone augmentation of clozapine worsened
verbal working memory, while this outcome improved in the
group that remained on a single antipsychotic.47
The RCTs had small sample sizes (16–68 patients), were rel-
atively brief (lasting from 6 to 12 weeks), and focused on a nar-
row selection of antipsychotics. Five of the six trials examined
antipsychotic augmentation of clozapine.47–50,52 In four trials, the
Copyright 2008 Joint Commission on Accreditation of Healthcare Organizations
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Reference
Anil-
Yagcioglu47
2005
Freudenreich48
2007
Honer49 2006
Josiassen50
2005
Kotler51 2004
Shiloh52 1997
Agelink53
2004
Design
Double blind (DB) RCT
comparing clozapine with
clozapine/risperidone
patients with 
schizophrenia partially
responsive to clozapine
monotherapy
DB RCT comparing cloza-
pine with clozapine/risperi-
done in patients with
stable residual symptoms
of schizophrenia 
DB RCT comparing cloza-
pine with clozapine/
risperidone in patients
with schizophrenia and
schizoaffective disorder
poorly responsive to
clozapine monotherapy
DB RCT comparing cloza-
pine with clozapine/risperi-
done in patients with
schizophrenia and
schizoaffective disorder
unresponsive or partially
responsive to clozapine
monotherapy
RCT comparing olanza-
pine with olanzapine/
sulpiride in patients with
treatment-resistant schizo-
phrenia receiving olanza-
pine monotherapy
DB RCT comparing cloza-
pine with clozapine/sulpiri-
de in patients with
schizophrenia partially
responsive to clozapine
monotherapy
Open-label, observational
study of amisulpride
added to clozapine for
psychosis
or schizoaffective disorder
unresponsive to clozapine
monotherapy
Clinical Outcomes
■ Monotherapy led to greater improvement
in positive symptoms overall on PANSS 
(p = .02; primary outcome).
■ Monotherapy led to greater improvement
in delusions.  
■ No difference between groups in quality of
life or functioning 
■ No difference between groups in symptom
improvement on PANSS (primary out-
come)
■ Multiple antipsychotics led to greater
improvement in disorganized thought 
subscale (p = .047).
■ No difference between groups in symptom
improvement on PANSS (primary 
outcome)
■ No difference between groups in 
number of responders 
■ Multiple antipsychotics led to worsening in
verbal working memory compared with
monotherapy (p = .02).
■ More patients responded on combination
(p < .01; primary outcome). 
■ Both groups experienced a reduction of
symptoms on BPRS (p < .0001).
■ Combination more effective at symptom
reduction than monotherapy (p < .04). 
■ No difference between groups in psychotic
and anxiety symptom improvement on
PANSS (primary outcome).
■ Multiple antipsychotics led to improvement
in depressive symptoms on HAMD
(p < .05).
■ Multiple antipsychotics led to significant
improvement in symptoms on BPRS 
(p < .05; primary outcome). 
■ Multiple antipsychotics led to significant
improvement in positive symptoms on
SAPS (p < .05).
■ Multiple antipsychotics led to significant
improvement on negative symptoms on
SANS (p < .05).
■ More patients responded in combination
treatment group (p < .02).
■ Multiple antipsychotics led to greater
improvement in symptoms on BPRS
(p < .05; primary outcome). 
Side Effects/Adverse Events
■ Multiple antipsychotics
increased sedation (p = .01).
■ Multiple antipsychotics
increased prolactin levels
(p < .0001).
■ No increase in QTc with com-
bination
■ Multiple antipsychotics
increased prolactin levels 
(p = .02).
■ Multiple antipsychotics led to
tachycardia (significant but no
p value given).
■ Multiple antipsychotics
increased fasting blood 
glucose (p < .04).
■ No difference in side effects
including weight, agranulocy-
tosis, and seizures 
■ No difference in extrapyrami-
dal side effects or weight
■ Multiple antipsychotics
increased prolactin levels 
4-to-7-fold (p < .05).
■ No changes in ECG in either
group
Comments
■ Response defined as
> 20% decrease in
symptoms
■ Response defined as
> 20% decrease in
symptoms on BPRS
■ Response defined as
> 20% decrease in
symptoms
(continued on page 574)
Randomized Clinical Trials (RCTs) Comparing Multiple Antipsychotics to Monotherapy
Table 1. Studies Comparing Multiple Antipsychotics to Antipsychotic Monotherapy Among 
Patients with Established Treatment Resistance to Monotherapy*
Observational, Noncontrolled Studies of Augmentation of Monotherapy to Multiple Antipsychotic
( (
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Reference
de Groot54
2001
Friedman55
1997
Henderson56
1996
Megna57 2007
Munro58 2004
Taylor59 2001
Ziegenbein60
2006
Design
Open-label, observational
study of risperidone
added to clozapine for
patients with persistent
symptoms of schizophre-
nia despite treatment with
clozapine monotherapy
Retrospective case review
of the addition of pimozide
in patients partially
responsive to clozapine
with schizophrenia or
schizoaffective disorder 
Open-label, observational
study of risperidone
added to clozapine for
residual symptoms of
schizophrenia and
schizoaffective disorder
Retrospective chart review
of patients treated with
single atypical antipsy-
chotic for at least 4
months followed by addi-
tion of second agent for
severe persistent schizo-
phrenia or schizoaffective
disorder
Open-label, observational
study of amisulpride
added to clozapine partial
or nonresponders with
schizophrenia
Open-label, observational
study of risperidone aug-
mentation of clozapine for
patients with schizophre-
nia and schizoaffective
disorder partially 
responsive to clozapine
Open-label, observational
study of aripiprazole aug-
mentation of clozapine for
treatment-resistant 
schizophrenia
Clinical Outcomes
■ No patients responded to treatment with
multiple antipsychotics on PANSS (n = 11).
■ Multiple antipsychotics led to greater
improvement in symptoms on BPRS 
(p = .03; primary outcome). 
■ Multiple antipsychotics led to greater
improvement in symptoms on BPRS
(p = .0002).
■ Multiple antipsychotics led to greater
reduction in positive symptoms on BPRS
(p = .001).
■ Multiple antipsychotics led to greater
reduction in negative symptoms on BPRS
(p = .004).
■ Multiple antipsychotics led to greater
reduction in depressive symptoms on
BPRS (p = .02).
■ 26% average reduction in symptoms fol-
lowing treatment with multiple antipsy-
chotics on BPRS (p = .016).
■ Multiple antipsychotics led to greater
improvement in symptoms on PANSS,
SANS, GAF, BPRS (p < .0001).
■ Depression and anxiety did not improve
with multiple antipsychotics.
■ Significant improvement in symptoms with
combination on PANSS (p = .0002)
■ Significant improvement in symptoms with
combination in positive (p = .0003), 
negative (p = .0004), and general 
psychopathology (p = .0007)
■ Significant improvement in symptoms with
combination on BPRS (p < .05)
Side Effects/Adverse Events
■ No changes in extrapyramidal
side effects or labs
■ 1 dropout due to orthostatic
hypotension 
■ Not reported 
■ Worsened akathisia (33%)
hypersalivation with (42%)
multiple antipsychotics (NS) 
■ 1 increased fatigue vs. 6
decreased fatigue following
augmentation (NS)
■ Increased use of side effect
medications following multiple
antipsychotics (p < .04)
■ Multiple antipsychotics 
significantly elevated prolactin
(p < .0001).
■ One patient had worsening of
compulsive behaviors.
■ Increased side effects over
the first two weeks of the mul-
tiple antipsychotics that
resolved over time 
■ No significant QTc changes
with multiple antipsychotics
Comments
■ Response defined as
> 20% symptom
reduction 
■ Decreased use of
PRN antipsychotics
following augmenta-
tion of standing regi-
men to multiple anti-
psychotics (p < .04)
■ No patients improved
sufficiently to be 
discharged 
■ Clozapine doses were
lowered an average of
16%.
Observational, Noncontrolled Studies of Augmentation of Monotherapy to Multiple Antipsychotic
Table 1. Studies Comparing Multiple Antipsychotics to Antipsychotic Monotherapy Among 
Patients with Established Treatment Resistance to Monotherapy* (continued)
(continued on page 575)
Copyright 2008 Joint Commission on Accreditation of Healthcare Organizations
augmenting agent was risperidone,47–50 whereas in the fifth it
was sulpiride52, an SGA not available in the United States. The
sixth trial compared the combination of olanzapine and sulpir-
ide with olanzapine monotherapy.51
We identified nine noncontrolled observational trials com-
paring antipsychotic polypharmacy to monotherapy in samples
with established treatment resistance to trials of a single
antipsychotic (Table 1).53–61 All studies were of patients with
schizophrenia or schizoaffective disorder. Eight of the trials
reported significant improvement in reduced symptoms with
the addition of a second antipsychotic.53,55–61 Of the eight stud-
ies that examined side effects, four reported no change with the
addition of a concurrent antipsychotic.53,54,59,60 Three studies
reported increased side effects with the addition of another
antipsychotic,56–58 whereas one study reported a decrease in
sedation.56
The observational studies also had small sample sizes (7–28
patients), and most of them were longer than the RCTs (1–9
months). As with the more rigorous trials, these studies focused
on a narrow selection of antipsychotics. Of the nine trials, eight
involved clozapine augmentation.53–56,58–61 Clozapine was aug-
mented with risperidone in three studies;54,56,59 amisulpride (a
second-generation drug not available in the United States) in
two trials;53,58 and pimozide55, aripiprazole,60 and ziprasidone61
each in one trial. The ninth trial reported on the nonspecific
use of two SGAs in combination.57
SAMPLES WITHOUT ESTABLISHED TREATMENT
RESISTANCE TO ANTIPSYCHOTIC MONOTHERAPY
We identified three RCTs that compared antipsychotic
polypharmacy to monotherapy in samples without established
treatment resistance to a single antipsychotic (Table 2, pages
576–578).60–62 All three studies were of patients with schizo-
phrenia or schizoaffective disorder. None of the three trials
found clinical outcomes from multiple antipsychotics to be sig-
nificantly better than outcomes from a single antipsychotic.62–64
Of the two trials that studied side effects, one62 reported wors-
ened constipation and sedation in the multiple-antipsychotic
group, while the other64 reported reduced prolactin levels with
aripiprazole augmentation.
We identified six nonrandomized controlled trials that com-
pared antipsychotic polypharmacy to monotherapy in samples
without established treatment resistance to a single antipsychot-
ic (Table 2).65–70 Three of the trials studied samples with mixed
diagnoses,65–67 whereas three studied schizophrenia or schizoaf-
fective disorder.68–70 Of the four trials reporting clinical out-
comes, three reported no improvement,65,66,69 while the fourth
study reported mixed results.70 Multiple antipsychotics were
more beneficial than monotherapy at lower dosages but no bet-
ter than monotherapy at higher dosages.70 Four of the six stud-
ies reported on side effects—three reported a trend toward
greater side effects with multiple antipsychotics66,68,70 and the
fourth reported significantly greater side effects in this group.68
We identified six noncontrolled observational studies that
examined the relationship between antipsychotic polypharma-
cy and clinical outcomes in samples without documented treat-
ment resistance to monotherapy (Table 2).71–76 One study did
not report on clinical outcomes.71 Three of the studies evaluat-
ed the addition of a second antipsychotic to an existing antipsy-
chotic72,74,75; two studies found no improvement in
575October 2008      Volume 34 Number 10
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Reference
Ziegenbein61
2005
Design
Open-label, observational
study of ziprasidone-
clozapine combination for
treatment-resistant 
schizophrenia  
Clinical Outcomes
■ Significant improvement in symptoms with
combination on BPRS (p = .013)
Side Effects/Adverse Events
■ Side effects reported with mul-
tiple antipsychotics: 2 patients
each with increased sedation,
decreased sedation, hyper-
salivation, weight loss; 1
patient each with increased
LFTs, tremor, EEG changes;
hypotension (all NS)
Comments
■ Multiple antipsychotics
accompanied by 18%
reduced total daily
dose of clozapine 
* PANSS, Positive and Negative Syndrome Scale; QTc, Q-T interval corrected for heart rate; BPRS, Brief Psychiatric Rating Scale; HAMD, Hamilton Depression
(Scale); SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; ECG, electrocardiogram; NS, not sig-
nificant;  PRN, as needed; GAF, Global Assessment of Functioning (Scale); LFTs, liver function tests; EEG, electroencephalogram.    
Observational, Noncontrolled Studies of Augmentation of Monotherapy to Multiple Antipsychotic
Table 1. Studies Comparing Multiple Antipsychotics to Antipsychotic Monotherapy Among 
Patients with Established Treatment Resistance to Monotherapy* (continued)
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Reference
Potkin62 2002
Potter63 1989
Shim64 2007
Centorrino65
2005
Design
An open-label RCT com-
paring quetiapine alone in
initial period with quetiap-
ine combination (randomly
assigned to haloperidol,
risperidone, or thiorida-
zine) for patients in 
remission from psychotic
symptoms in schizophre-
nia, bipolar, or schizoaf-
fective disorder
RCT of chlorpromazine
alone, clozapine alone, or
chlorpromazine + clozap-
ine for schizophrenia
Double blind (DB) RCT of
augmentation of haloperi-
dol with aripiprazole for
patients with hyperpro-
lactinemia on haloperidol
for clinically stable schizo-
phrenia.    
Retrospective matched
control trial comparing
hospitalized patients treat-
ed with multiple antipsy-
chotics or monotherapy
for mixed diagnoses
Clinical Outcomes
■ No significant differences in symptom
change between multiple-antipsychotic
groups and monotherapy group on BPRS
or CGI
■ Multiple antipsychotics were no better than
monotherapy with clozapine in reducing
overall symptom levels on BPRS.
■ No significant change in symptoms
observed with augmentation on BPRS
■ Multiple antipsychotics were no better than
monotherapy for symptom reduction  on
PANSS, CGI, GAF.
Side Effects/Adverse Events
■ Risperidone + quetiapine
increased sleepiness 
(p < .05).
■ Haloperidol + quetiapine
increased constipation 
(p < .05).
■ Not reported 
■ Prolactin normalized on
haloperidol-aripiprazole 
(p < .0001; primary outcome)
■ Dry mouth (31%), headache
(23%), insomnia (42%), and
weakness occurred more fre-
quently in augmentation group
(NS).
■ EPS improvement in 20% of
augmented patients (NS) 
■ 2 patients withdrew because
of insomnia, irritability, and
anxiety on combination.
■ Not reported
Comments
■ Study’s primary intent
was to assess for
drug interactions; also
examined clinical out-
comes and other side
effects.
■ Short study period:
initial monotherapy
phase of > 7 days,
followed by combina-
tion phase of 8.5 days 
■ Clozapine with or
without chlorpro-
mazine was more
effective in reducing
selected positive
symptoms than chlor-
promazine alone.
■ Study’s primary intent
was to assess poten-
tial of augmentation to
lower prolactin levels;
also examined clinical
outcomes and other
side effects.
■ Total antipsychotic
dose 2.1 times
greater with multiple
antipsychotics com-
pared with monother-
apy (p = .005)
■ Matching based on
age, gender, diagno-
sis, and admission
clinical ratings
■ Patients on multiple
antipsychotics had
more positive symp-
toms at admission
and discharge com-
pared with monother-
apy (p < .0001; 
p = .002).
(continued on page 577)
Randomized Controlled Trials (RCTs) Comparing Multiple Antipsychotics to Monotherapy
Table 2. Studies Comparing Multiple Antipsychotics to Antipsychotic Monotherapy Among Patients Without Established 
Treatment Resistance to Monotherapy
Nonrandomized Controlled Studies Comparing Multiple Antipsychotics to Monotherapy
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Reference
Centorrino66
2004
Correll67 2007
Henderson68
2001
Knight69
1979
Nishikawa70
1985
Ganesan71
2007
Henderson72
2006
Design
Retrospective matched
control trial comparing
patients treated with multi-
ple antipsychotics or
monotherapy for mixed
diagnoses
Cross-sectional study of
multiple antipsychotics
with at least one atypical
compared with atypical
antipsychotic monothera-
py on risk of metabolic
syndrome in mixed 
diagnoses
Matched case control
study examining effects
on prolactin levels of
risperidone added to
clozapine compared with
clozapine alone for schiz-
ophrenia
DB controlled crossover
trial comparing thiothixene
with combination of triflu-
operazine and chlorpro-
mazine for schizophrenia
Controlled trial comparing
combination of pimozide
and thioridazine with each
drug individually to pre-
vent reemergence of
symptoms in asympto-
matic patients with schizo-
phrenia
Retrospective study com-
paring multiple antipsy-
chotics to monotherapy
for mixed diagnoses
Prospective observational
study of the effects of
aripiprazole added to
clozapine for schizophre-
nia 
Clinical Outcomes
■ Multiple antipsychotics were no better than
monotherapy for symptom reduction  on
PANSS, CGI, and GAF.
■ Not reported
■ Not reported
■ Multiple antipsychotics were no better than
monotherapy for symptom or behavioral
improvement on BPRS
■ Mixed results based on dosage of
monotherapy agents. Multiple antipsy-
chotics associated with more symptom-
free days in comparison to lower-dose
monotherapy groups but not significantly
different in comparison to higher-dose
monotherapy groups.
■ Not reported
■ Multiple antipsychotics did not significantly
improve average symptom levels com-
pared with monotherapy on PANSS
Side Effects/Adverse Events
■ Higher adverse events with
multiple antipsychotics (NS)
■ Risk of additional medication
for EPS was 40% with multi-
ple antipsychotics compared
with 25.7% with monotherapy
(NS).
■ Adverse events higher with
higher total daily doses
■ Risk of metabolic syndrome
was not significantly higher
with multiple antipsychotics
compared with monotherapy
in multivariate analysis con-
trolling for clinical and
sociodemographic factors.
■ Multiple antipsychotic use
associated with significant
increases in prolactin, weight,
and BMI compared with
monotherapy (p < .0001, p =
.0296, p = .0273)
■ Increased side effects with
combination (NS)
■ Signs of “overdose” more
common with combination
■ No difference in side effects
between groups on UKU
■ Significant decreases in
weight and BMI, cholesterol,
TG, HDL, and fatigue with
addition of aripiprazole 
(p = .003, p = .004, p = .002,
p = .04,  p = .015)
Comments
■ Total daily dose of
antipsychotic 78%
higher with multiple
antipsychotics 
(p < .001)
■ Length of stay longer
with APP (p < .001)
■ Matched for age and
gender only
■ Patients not matched
but similar at baseline
■ Monotherapy patients
on more antidepres-
sants (p < .001)
Nonrandomized Controlled Studies Comparing Multiple Antipsychotics to Monotherapy
Table 2. Studies Comparing Multiple Antipsychotics to Antipsychotic Monotherapy Among Patients Without Established 
Treatment Resistance to Monotherapy (continued)
Noncontrolled Studies Comparing Multiple Antipsychotics to Monotherapy
(continued on page 578)
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symptoms,72,75 while one study reported no clinical effects.74
The remaining two studies had a different design, using regres-
sion analysis to assess the association between antipsychotic
polypharmacy and premature death in patients with schizo-
phrenia.73,76 Controlling for multiple sociodemographic and
clinical factors, both studies found that use of two or more
antipsychotics was associated with increased mortality. Five of
the six studies reported on side effects.71–75 Two found that
antipsychotic polypharmacy was associated with improved side
effects,72,74 one with worsening,73 and the other with no differ-
ence.71,75
Discussion
Despite the high prevalence of antipsychotic polypharmacy, the
Reference
Joukamaa73
2006
Reinstein74
1999
Tapp75 2005
Waddington76
1998
Design
Retrospective observa-
tional study of mortality in
patients treated with 0, 1,
2, or > 3 antipsychotics for
schizophrenia  
Retrospective study of
patients who developed
diabetes on clozapine
monotherapy and were
switched to clozapine-
quetiapine combination for
schizophrenia  
Retrospective study of the
effect of addition of a sec-
ond antipsychotic com-
pared with monotherapy
for psychotic disorders
Prospective observational
study of mortality in
patients diagnosed with
schizophrenia at a long-
term inpatient facility
Clinical Outcomes
■ Relative risk for death per increment of
each additional antipsychotic was 2.5
(95% CI, 1.46–4.30).
■ No adverse behavioral changes with 
addition of quetiapine
■ Treatment with multiple antipsychotics did
not improve symptoms compared with
monotherapy on PANSS.
■ Relative risk of death among patients
treated with multiple antipsychotics was
2.46 (95% CI, 1.10–5.47; p = .03).
Side Effects/Adverse Events
■ HDL decreased associated
with combination (p < .001)
■ Mean weight loss 9.2 lbs. 
(p < 0.001)
■ Improved diabetes (p < .001)
■ Clinician ratings of EPS were
unchanged with the addition
of second antipsychotic on
ESRS.
■ Patient’s subjective reports of
EPS significantly increased by
22% with addition of second
antipsychotic.
■ Not reported
Comments
■ 17-year study with
group assignment
based on number of
antipsychotics at
baseline
■ Multivariate analysis
adjusting for age,
gender, somatic dis-
eases, lifestyle, and
risk factors (i.e.,
smoking, exercise,
alcohol, body mass
index, level of educa-
tion)
■ 10-year study with
group assignment
based on maximum
number of antipsy-
chotics prescribed
concurrently
■ Other risk factors
associated with earlier
death were edentu-
lousness, absence of
treatment with anti-
cholinergic medica-
tions, and time since
last antipsychotic
treatment
Noncontrolled Studies Comparing Multiple Antipsychotics to Monotherapy
Table 2. Studies Comparing Multiple Antipsychotics to Antipsychotic Monotherapy Among Patients Without Established 
Treatment Resistance to Monotherapy (continued)
* BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impression (Scale); EPS, extrapyramidal side affects; PANSS, Positive and Negative Syndrome Scale;
GAF, Global Assessment of Functioning (Scale); BMI, body mass index; NS, not significant; UKU, The Udvalg for Kliniske Undersøgelser Side Effect Rating Scale;
TG, triglycerides; HDL, high-density lipoprotein; CI, confidence interval; ESRS, Extrapyramidal Symptoms Rating Scale.
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data in support of this practice are limited and narrowly
focused. Among patients with established treatment resistance
to previous trials of antipsychotic monotherapy, RCTs showed
mixed results in clinical outcomes and generally greater side
effects with multiple antipsychotics. Positive clinical findings
were limited to studies that either included SGAs unavailable in
the United States or augmentation of clozapine, a unique
antipsychotic with relative low utilization in the United States
because of risks of agranulocytosis and need for close monitor-
ing.62–64 The findings support wider use of clozapine, which
practice guidelines recommend be tried before use of multiple
antipsychotics.42–44 The findings also emphasize the need for
further research on augmentation strategies using a wider range
of antipsychotics.  
On the other hand, among patients who do not meet the
guideline recommendation of multiple unsuccessful trials of a
single antipsychotic before the addition of a second, research
studies do not support use of multiple antipsychotics. Three
RCTs and five of six nonrandomized controlled trials found
multiple antipsychotics to be no better than a single antipsy-
chotic in improving primary clinical outcomes. The sixth con-
trolled trial showed mixed results based on dose. Data on side
effects were limited in these studies
but generally suggested that
polypharmacy was associated with
greater side effects.  
In both groups, studies with more
rigorous designs (that is, RCTs and
other controlled studies) were more
likely to show a lack of benefit from
polypharmacy than studies with less
rigorous designs. A limitation of
these trials is that few studies con-
firmed patient adherence, either
through blood levels or other means,
with antipsychotic medications as
prescribed.
In light of concern over the high
prevalence of antipsychotic poly-
pharmacy and the evidence from
research studies, the Joint Com-
mission has adopted two measures of
antipsychotic polypharmacy as part
of its recently issued core measure set
for Hospital-Based Inpatient
Psychiatric Services (HBIPS; Figure
1, left).36  The first measure reports
hospitals’ rate of patients discharged on two or more routinely
scheduled antipsychotics. The second examines whether
patients discharged on two or more antipsychotics have a doc-
umented, clinically appropriate justification for use of multiple
agents. 
In developing these and the five other HBIPS measures, the
Joint Commission brought together a technical advisory panel36
representing a range of stakeholder perspectives. Part of the
panel’s role was to identify clinically appropriate justifications
for multiple antipsychotics. The first two justifications come
directly from practice guidelines and research studies: a history
of multiple unsuccessful trials of monotherapy and augmenta-
tion of clozapine. The third justification reflects a reality of
contemporary inpatient psychiatric care. In this era of short
inpatient stays, the primary focus of hospitalization for acute
episodes of psychotic conditions is stabilization, followed by
transfer to a less intensive level of care for ongoing treatment.
Under these circumstances, inpatient clinicians often add a new
antipsychotic to an existing one but discharge the patient
before the original antipsychotic can be safely tapered off.
Among patients who have not had multiple trials of monother-
apy, discontinuation of the initial agent can be completed by
Figure 1. The core measures are shown, along with denominators and numerators. Source: The Joint
Commission: Specification Manual for National Quality Measures––Hospital Based Inpatient Psychiatric
Services Psychiatric Core Measure Set (Version 2.0a). Jul. 2008. 
http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Hospital+Based+
Inpatient+Psychiatric+Services.htm (last accessed Aug. 20, 2008). 
The Joint Commission’s Hospital-Based
Inpatient Psychiatric Service (HBIPS) 
Core Measures on Antipsychotic Polypharmacy
1. Patients discharged on multiple antipsychotic medications
Denominator: Psychiatric inpatients discharged on one or more routinely scheduled antipsychotic
medications
Standing antipsychotics only 
Planned discharges only
Numerator: Inpatients from the denominator who are discharged on two or more routinely 
scheduled antipsychotic medications
2. Patients discharged on multiple antipsychotic medications with appropriate justification
Denominator: Psychiatric inpatients discharged on two or more routinely scheduled antipsychotic
medications
Standing antipsychotics only 
Planned discharges only
Numerator:   Inpatients from the denominator discharged on two or more routinely scheduled
antipsychotic medications with appropriate justification, i.e., is there documentation in
the medical record of:
A history of three or more failed trials of monotherapy
Recommended plan to taper to monotherapy in continuing care plan
Clozapine augmentation
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the provider of the next level of care. Thus, the third clinically
appropriate rationale built into the measure is as follows:
documented communication to the patient’s after-care clinician
of a continuing care plan recommending a taper to monother-
apy.
The advisory panel considered other reasons that psychia-
trists may have for prescribing multiple antipsychotics, includ-
ing those proposed in Joint Commission focus groups and in
response to calls for public comment. No other rationales were
adequately supported by research evidence or by consensus
judgments of expert clinicians.
Reducing unnecessary antipsychotic polypharmacy poses
several challenges to inpatient psychiatric units and the hospi-
tal systems that support them. Documentation of a patient’s
past antipsychotic trials often is missing or incomplete, or is
spread over several volumes of old medical records. Improving
performance will likely require that inpatient units adopt sys-
tematic processes to maintain accessible, up-to-date informa-
tion on previous antipsychotic treatment—including
documentation of past drug trials and their duration, clinical
response, and side effects. Another challenge is that communi-
cation between inpatient and outpatient clinicians following a
hospital stay varies widely.77 Although discharge summaries are
routinely completed at or near time of discharge, they often are
not sent to providers at the next level of care in a timely fash-
ion. Patients with psychotic illnesses can be a limited conduit
for providing treatment plan information and may or may not
have family members, case managers, or others who serve this
role. Improving communication between hospital and
providers of the next level of care is the primary goal of anoth-
er HBIPS measure and is an important component of avoiding
unnecessary antipsychotic polypharmacy by communicating
the inpatient psychiatrist’s intentions regarding antipsychotic
medications.
A final challenge is not limited to this quality measure but is
common to all QI activities based on process measures that can
be influenced by multiple providers, clinical settings, and
patients themselves. Will inpatient clinicians and managers be
able to focus on and act on that part of unnecessary antipsy-
chotic polypharmacy that is under their control, as opposed to
that which is determined by others? It is unlikely that even the
most evidence-based, conscientious, and effective inpatient
units will achieve perfect performance on even the second
measure, any more than adult inpatient units can truly reduce
restraint rates to zero if they admit agitated, assaultive psychot-
ic patients. However, just as many facilities, including state
mental health systems, have achieved significant decreases in
physical restraint use through education, training, innovative
procedures, and enhanced communication,78,79 it is likely that
inpatient teams can also reduce the rate of unnecessary antipsy-
chotic polypharmacy. 
Several interventions to reduce multiple antipsychotic use
have achieved promising results. For example, Suzuki et al. con-
verted 22 of 44 patients (initially treated with an average of
three antipsychotics) to a single antipsychotic. Of the 22
patients on monotherapy, 8 showed symptomatic improve-
ment, whereas symptom levels for the other 14 were
unchanged.80 Dissemination of treatment algorithms alone has
not been found to be effective,16 but Chong et al. reported that
combining treatment algorithm implementation with periodic
audits of algorithm compliance significantly decreased antipsy-
chotic polypharmacy.19 Thompson et al. achieved a modest
reduction using a multifaceted approach combining group edu-
cation, academic detailing, and chart reminders. The literature
on interventions to reduce antipsychotic polypharmacy is
extensive; review of these studies would be timely. In addition,
rigorously designed trials evaluating current best practices
would be of value to inpatient clinicians and managers.
While we have chosen to focus this review on the clinical
impact of antipsychotic polypharmacy, other authors have
described the financial impact of this practice.81,82 Financial
concerns have led many payers to implement formulary restric-
tions on antipsychotic use. These restrictions are often more
sweepingly restrictive than evidence-based guideline recom-
mendations for multiple antipsychotic use.83
Conclusion
Research evidence only supports the use of antipsychotic
polypharmacy in treatment-resistant patients, primarily when
augmenting clozapine with an SGA. Treatment guidelines rec-
ommend not resorting to antipsychotic polypharmacy until
after multiple failed trials of antipsychotic monotherapy,
including clozapine. Ultimately, the value of assessing and
reducing rates of antipsychotic polypharmacy requires the
demonstration of improved clinical outcomes and/or reduced
side effects after converting patients from multiple, unjustified
antipsychotics to monotherapy. Ideally, this should be done
through RCTs that provide definitive evidence of causality.
However, the implementation of a nationwide quality measure
offers an excellent, naturalistic opportunity to validate the
measure by examining the association between improved per-
formance and patient outcomes. Further research is also need-
ed to identify the most effective (and cost-effective) methods
for achieving improved performance. J
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